FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Forschung/Highlighting the novel mechanism by which MOTS-c and TRIM72 contribute to plasma membrane repair, emphasizing potential implications for future therapeutic interventions.
Zurück zur Forschungsbibliothek
MOTS-cTRIM72

Highlighting the novel mechanism by which MOTS-c and TRIM72 contribute to plasma membrane repair, emphasizing potential implications for future therapeutic interventions.

May 16, 2026
Share

Quellpapier

Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating the translocation of TRIM72 to membrane.

Jia Hong et al.Theranostics2024
Emergierende Forschung

Basiert auf emergierender Forschung. Diese Erkenntnisse sind versprechend, aber erfordern weitere Validierung.

Über diese Analyse

Diese Artikel zerlegen die Ergebnisse des obigen Quellpapiers in verständliche Sprache für die Peptidforschungscommunity. Unser Ziel ist es, das Wichtigste hervorzuheben — die praktischen Implikationen, den Stärke der Beweise und was dies für laufende Forschung bedeutet.

MOTS-c: A New Player in Cellular Protection Through Membrane Repair

Published: May 16, 2026 | Source: Theranostics (2024) | Category: MOTS-c, TRIM72

Overview

A recent review published in Theranostics highlights the role of mitochondria-encoded peptide MOTS-c in facilitating plasma membrane repair by promoting the translocation of TRIM72 to cell membranes. This discovery could pave the way for innovative therapeutic strategies targeting cellular damage and repair mechanisms.

Study Background

Previous research has shown that mitochondrial peptides play crucial roles in various physiological processes, including metabolism and stress response. However, their involvement in direct cellular protection through plasma membrane repair was less understood until now. The review synthesizes existing literature to elucidate the mechanism by which MOTS-c interacts with TRIM72, a protein known for its role in cell survival pathways.

What the Research Found

The review emphasizes that MOTS-c acts as a signaling molecule within cells, facilitating the movement of TRIM72 from intracellular locations to the plasma membrane. This translocation is critical during cellular stress or injury when rapid repair mechanisms are necessary to maintain cell integrity and function. The study suggests that without MOTS-c, the efficiency of TRIM72 in reaching the damaged sites on the plasma membrane would be significantly reduced.

What This Means for Peptide Users

While this research does not directly offer new peptides for therapeutic use, it opens avenues for developing drugs or treatments that mimic or enhance the function of MOTS-c. Future studies might explore how to increase the production or activity of MOTS-c in cells affected by diseases characterized by membrane damage and repair deficits.

Limitations and Caveats

As a review paper, this study does not present new experimental data but rather synthesizes findings from previous research. Therefore, its conclusions are contingent on the limitations inherent in earlier studies such as sample size, animal model applicability to human conditions, and variability across different cell types or disease states.

How This Compares to Previous Research

The review aligns with growing interest in mitochondrial peptides' roles beyond energy metabolism. It builds upon earlier work that hinted at MOTS-c’s broader cellular functions but did not specifically focus on its role in plasma membrane repair mechanisms. The novel aspect here is the detailed exploration of how MOTS-c interacts with TRIM72 to facilitate membrane repair.

Our Analysis

PeptideVault views this review as a significant contribution to understanding mitochondrial peptides' multifaceted roles in cellular physiology and pathology. However, it underscores the need for further experimental validation to confirm the mechanisms described and explore their therapeutic potential fully.

Key Takeaways

  • MOTS-c Facilitates Repair: MOTS-c plays a crucial role in plasma membrane repair by assisting TRIM72's translocation.
  • Potential Therapeutic Targets: The findings suggest possible new targets for therapies aimed at enhancing cellular protection mechanisms.
  • Further Research Needed: While promising, the conclusions require confirmation through additional experimental studies.

Original Source

Citation: Jia Hong, Zhou Lyu-Chen, Chen Yong-Feng et al. (2024). Mitochondria-encoded peptide MOTS-c participates in plasma membrane repair by facilitating the translocation of TRIM72 to membrane.. Theranostics. DOI: 10.7150/thno.100321

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Bearbeitungsnotiz

Diese Analyse wurde vom Peptide Contacts-Forscherteam erstellt. Wir ermutigen Leser, die volle Quellpapier für vollständige Methoden und Daten. Die ursprüngliche Veröffentlichung ist auf PubMed.

Verwandte Forschungen

Comments

Sign in to join the discussion

Diese Analyse basiert auf peer-bewerteter Forschung zur Bildungszwecke. Sie bildet keine medizinische Beratung aus. Stets beraten Sie sich mit einer qualifizierten Gesundheitsversorgerin, bevor Sie irgendeine Peptidbasierte Therapie verwenden.